Literature DB >> 10727438

Benchmarks for antiretroviral therapy.

O J Cohen1, A S Fauci.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10727438      PMCID： PMC377468          DOI： 10.1172/JCI9590

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  25 in total

1.  Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy.

Authors:  C D Pilcher; W C Miller; Z A Beatty; J J Eron
Journal:  AIDS       Date:  1999-07-30       Impact factor: 4.177

2.  Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.

Authors:  G P Rizzardi; R J De Boer; S Hoover; G Tambussi; A Chapuis; N Halkic; P A Bart; V Miller; S Staszewski; D W Notermans; L Perrin; C H Fox; J M Lange; A Lazzarin; G Pantaleo
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

Review 3.  Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.

Authors:  C C Carpenter; D A Cooper; M A Fischl; J M Gatell; B G Gazzard; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; M Schechter; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  2000-01-19       Impact factor: 56.272

4.  Latent reservoirs of HIV: obstacles to the eradication of virus.

Authors:  T W Chun; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

5.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.

Authors:  G Dornadula; H Zhang; B VanUitert; J Stern; L Livornese; M J Ingerman; J Witek; R J Kedanis; J Natkin; J DeSimone; R J Pomerantz
Journal:  JAMA       Date:  1999-11-03       Impact factor: 56.272

6.  Predictors of optimal virological response to potent antiretroviral therapy.

Authors:  W G Powderly; M S Saag; S Chapman; G Yu; B Quart; N J Clendeninn
Journal:  AIDS       Date:  1999-10-01       Impact factor: 4.177

7.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS.

Authors:  J Embretson; M Zupancic; J L Ribas; A Burke; P Racz; K Tenner-Racz; A T Haase
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

8.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.

Authors:  G Pantaleo; C Graziosi; J F Demarest; L Butini; M Montroni; C H Fox; J M Orenstein; D P Kotler; A S Fauci
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

9.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

10.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962
View more
  1 in total

1.  Putative roles of purinergic signaling in human immunodeficiency virus-1 infection.

Authors:  Paulo A F Pacheco; Robson X Faria; Leonardo G B Ferreira; Izabel C N P Paixão
Journal:  Biol Direct       Date:  2014-10-29       Impact factor: 4.540
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.